Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0406810 (
NAME
)
13,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
E14a3 breakpoint cluster region (BCR)/ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL) fusion transcript is rare in Philadelphia chromosome positive disease, particularly in acute lymphoblastic leukemia (ALL). Recently an e14a3 fusion transcript was detected by multiple laboratory examinations, and the patient was suffering from ALL. Except for the
BCR/ABL fusion
gene, in the present study the patient additionally had an IKAROS family zinc finger 1 deletion which, has been confirmed as a significant adverse prognosis factor. Following 2 rounds of chemotherapy, the patient presented cytological remission; however, the patient then relapsed 2 months later. They then received chimeric antigen receptor modified (CAR-modified) T-cell therapy and achieved complete remission.
CAR
-modified T-cell therapy is a powerful novel therapy which, exhibited great potential for treating refractory ALL, regardless of the existence and form of the
BCR/ABL fusion
transcript.
...
PMID:A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy. 2943 63
Effective treatments for relapsed Ph
+
ALL with T315I mutation are few; CD19
CAR
T-cell therapy are a potential therapy for this condition. We reported 7 patients with relapsed Ph
+
ALL with T315I mutation, who were treated pre- or post-allo-HSCT with CD19-specific
CAR
T-cells. Of the 7 cases, 6 were in CR or CRp within 1 month after the first infusion of
CAR
T-cells. MRD revealed a rapid decline in 6 patients.
BCR/ABL fusion
transcripts were negative in 4/5 cases (not performed in 2). Three patients maintained remission without evidence of MRD by QPCR until the final follow-up, of which 2 received anti-CD19
CAR
T-cells and ponatinib at the same time. Our study confirmed the efficacy of anti-CD19
CAR
T-cell therapy in treatment of relapsed Ph
+
ALL with T315I mutation pre- or post-allo-HSCT and the concurrent applicability of this therapy with ponatinib.
...
PMID:Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation. 3151 42
